MONTREAL, May 16, 2017 /CNW Telbec/
- Theratechnologies Inc. (TSX: TH) today held its annual
meeting of shareholders.
As part of the meeting, shareholders proceeded to elect the
Company's Board of Directors for a one-year term and elected KPMG
LLP, as auditors for the current fiscal year. In addition,
shareholders adopted a resolution modifying the share option plan
of the Company entitling the Board of Directors to make certain
amendments to the plan without seeking shareholder approval.
All candidates proposed for the position of directors were
elected in the following proportion:
|
# IN
FAVOUR
|
% IN
FAVOUR
|
ABSENTION
|
%
ABSTENTION
|
Gérald A.
Lacoste
|
26,635,296
|
99.27
|
195,357
|
0.73
|
Dale
MacCandlish-Weil
|
26,694,076
|
99.49
|
136,577
|
0.51
|
Paul
Pommier
|
26,501,133
|
98.77
|
329,520
|
1.23
|
Dawn
Svoronos
|
26,669,913
|
99.40
|
160,740
|
0.60
|
Jean-Denis
Talon
|
26,497,133
|
98.76
|
333,520
|
1.24
|
Luc
Tanguay
|
26,672,738
|
99.41
|
157,915
|
0.59
|
In addition to reviewing highlights from last year, both Mrs.
Svoronos and Mr. Luc Tanguay,
respectively Chair of the Board and President and CEO of
Theratechnologies, shared their vision as to where the Company
would be heading in the coming years.
"Ever since regaining commercial rights to
EGRIFTA®, the future has never looked brighter
for Theratechnologies. We have quickly been able to appreciate just
how much leverage we gained. With the potential launch of
ibalizumab in the United States,
we are now poised to reach new levels of growth and to give our
company even more momentum," said Luc
Tanguay, President and CEO, Theratechnologies Inc.
"We are also thrilled with the acquisition of the commercial
rights for ibalizumab in Europe.
We concluded a great agreement with our partner TaiMed for this
territory. If approved in Europe,
ibalizumab will further support mid and long-term growth for our
company and shareholders," added Mr. Tanguay.
"The Board is quite pleased with how management's strategic plan
is unfolding. I am very proud of what has been done thus far and I
am convinced that the best is yet to come," said Dawn Svoronos, Chair of the Board,
Theratechnologies inc.
"However, I am more than disappointed with the decision made by
the Government of Quebec to refuse
reimbursement of EGRIFTA® primarily for the
patients in Quebec who need the
drug. I wish our officials had enough vision to recognize what a
Quebec-based company has
accomplished and send the message that it supports Quebec-based research," added Dawn Svoronos.
About Theratechnologies
Theratechnologies (TSX: TH) is a specialty pharmaceutical
company addressing unmet medical needs to promote healthy ageing
and an improved quality of life among HIV patients. Further
information about Theratechnologies is available on the Company's
website at www.theratech.com and on SEDAR at www.sedar.com.
Forward-Looking Information
This press release contains statements that are considered
forward-looking information ("FLI") within the meaning of
securities laws that are based on our management's belief and
assumptions and on information currently available to our
management. You can identify forward-looking statements by terms
such as "may", "will", "should", "could", "would", "outlook",
"believe", "plan", "envisage", "anticipate", "expect" and
"estimate" or the negatives of these terms, or variations of them.
The forward-looking statements contained in this press release
include, but are not limited to, the approval of ibalizumab in
the United States and in
Europe for the treatment of MDR
HIV-1 infected patients and the growth of Theratechnologies based
on such approvals.
Forward-looking statements are based upon a number of
assumptions and are subject to a number of risks and uncertainties,
many of which are beyond Theratechnologies' control that could
cause actual results to differ materially from those that are
disclosed in or implied by such forward-looking information. These
assumptions include but are not limited to, the following: the BLA
submission will be accepted for review by the FDA, all data
obtained from the conduct of the Phase I, II and III clinical
trials will be sufficient to demonstrate the safety and efficacy of
ibalizumab and no other clinical trial will need to be conducted,
ibalizumab will be approved by the FDA and by European regulatory
authorities for the treatment of MDR HIV-1 infected patients and,
if approved, Theratechnologies will have set-up on time the
necessary infrastructure to launch and commercialize ibalizumab in
the United States and Europe. These risks and uncertainties include,
but are not limited to, the risk that the data obtained so far from
the Phase I, II and III clinical trials do not allow the FDA or a
European regulatory authority to approve ibalizumab, that
additional studies need to be conducted prior to the FDA or a
European regulatory authority approving ibalizumab, that the FDA
and/or a European regulatory authority does not approve ibalizumab
as a treatment for MDR HIV-1 infection and, if approved, that the
FDA and/or a European regulatory authority imposes a significant
limitation on its use resulting in a smaller patient population who
could benefit from ibalizumab.
We refer potential investors to the "Risk Factors" section of
our Annual Information Form (AIF) dated February 7, 2017 for additional risks and
uncertainties about Theratechnologies. The AIF is available on the
Company's website at www.theratech.com and on SEDAR at
www.sedar.com. The reader is cautioned to consider these and other
risks and uncertainties carefully and not to put undue reliance on
forward-looking statements. Forward-looking statements reflect
current expectations regarding future events and speak only as of
the date of this press release and represent our expectations as of
that date. We undertake no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise,
except as may be required by applicable law.
SOURCE Theratechnologies Inc.